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S U M M A R Y
The occurrence of bacillus Calmette–Gue´rin (BCG) disease following instillation for bladder cancer is
commonly documented. The intravesical administration of BCG is generally safe, but may present severe
complications. A fatal case of native aortic valve infectious endocarditis with septicemia due to BCG in a
patient treated with intravesical instillation is reported herein.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Bacillus Calmette–Gue´rin (BCG) is a live attenuated strain of
Mycobacterium bovis. The intravesical instillation of BCG has been
used as an alternative to chemotherapy in superﬁcial bladder
cancer. The most frequently reported adverse reactions are fever,
nausea, hematuria, and dysuria, which can occur 8–10 weeks after
the ﬁrst instillation. More severe complications include prostatic
infection, testicular tissue infection, miliary pneumonitis, granu-
lomatous hepatitis, bone marrow infection, and sepsis. Complica-
tions can occur 1 year after the initiation of treatment.1 A case of
native aortic valve infectious endocarditis with septicemia due to
BCG in a patient treated with intravesical instillation is reported
herein.
2. Case report
In January 2014, an 85-year-old man was admitted to the
Infectious Disease Department for the assessment of fever,
asthenia, anorexia, and weight loss. The patient, who had never
been vaccinated with BCG, had a history of bladder cancer treated
with transurethral resection of polyps in March 2013 and* Corresponding author. Tel.: +33 491 38 55 17; fax: +33 491 87 77 72.
E-mail address: didier.raoult@gmail.com (D. Raoult).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).intravesical instillations of BCG TICE strain from April 2013 to
December 2013. An early recurrence of the cancer had been
detected by cystoscopy in January 2014. On admission, transeso-
phageal echocardiography (TEE) revealed a bicuspid aortic valve
with a small mobile element. All clinical signs were considered
non-speciﬁc side effects of intravesical BCG therapy.
In April 2014, the patient was transferred to our department for
further assessment of prolonged fever and the onset of heart
failure. A second TEE showed a vegetation on the bicuspid aortic
valve, suggesting infectious endocarditis. Blood tests revealed
negative blood cultures, negative microbial serology, and a positive
rheumatoid factor at 37 UR/ml. Other routine laboratory tests were
within the normal range and showed an absence of leukocytosis
(white blood cells 6.38  109/l) and anemia (hemoglobin 118 g/l),
and a platelet count at 153  109/l. The patient had normal renal
and hepatic function and moderately elevated C-reactive protein
(68 mg/l). 18F-ﬂuorodeoxyglucose positron emission tomography
(18F-FDG PET) coupled with computed tomography (CT) showed
no hypermetabolic activity around the cardiac valves. A total body
CT showed a cerebral occipital embolism, bilateral pleural effusion,
and a thickening of the bladder. Acid-fast bacilli were found in
blood, sputum, and stool samples. Cultures of these three types of
sample were negative for common bacteria, but were positive for
BCG.
Ampliﬁcation and sequencing of the gene rpoB MycoB was
performed directly on the strain isolated and in the samples withciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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microbiological diagnosis was made, the 3-week treatment for
blood culture-negative endocarditis with vancomycin and genta-
micin was switched to rifampicin combined with isoniazid,
ethambutol, and pyrazinamide. The patient was not able to
undergo heart surgery because of his unstable general condition
and he died 2 weeks later.
3. Discussion
Disseminated M. bovis infection is commonly documented after
bladder infusion.1 In the present case, infectious endocarditis was
suspected using the modiﬁed Duke criteria incorporating TEE
ﬁndings (vegetation) as a major criterion and valvulopathy,
rheumatoid factor, and fever as three minor criteria. Endocarditis
was ﬁrmly diagnosed by isolation of M. bovis BCG from blood.
One reported case was found in the literature of a patient with
BCG infection of an implantable deﬁbrillator in the abdominal
position associated with spondylodiscitis, after intravesical
instillation of BCG for bladder cancer 5 months earlier.2 In that
patient, BCG was isolated in deﬁbrillator pocket, pericardium, and
lumbar tissue cultures. The patient was cured after 4 months of
antimicrobial therapy.
BCG treatment has been evaluated in a cohort of 1045 patients
with non-muscle invasive bladder cancer, including 143 patients
with a pacemaker, artiﬁcial heart valve, or orthopedic device.
Patients with a prosthetic device were found not to have an
increased risk of fever, infection, or treatment interruption because
of side effects compared with the general population.3
BCG is susceptible to most of the anti-tuberculosis drugs, with
the exception of pyrazinamide. The recommended treatment for
disseminated BCG disease includes a combination of anti-
tuberculosis drugs. Our patient was of advanced age and had a
recurrence of bladder cancer. A signiﬁcant association betweenolder age (>70 years) in those receiving BCG therapy and a poorer
prognosis of the bladder cancer has been noted,4 and the
occurrence of complications is more common. Our patient was
not vaccinated during his childhood and received BCG TICE. This
particular strain has been associated with a lack of efﬁcacy
compared to the Connaught BCG strains.5
This case shows that the generally safe intravesical adminis-
tration of BCG may present severe complications such as this
deadly infectious endocarditis.
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